SPOTLIGHT: Merck profits jump by 62 percent


Merck & Co. saw its profits soar by 62 percent to $1.53 billion, on a 12 percent jump in revenue and lower admin and overhead costs; Singulair was the big seller for the quarter at $1 billion. Release

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.